SEARCH

SEARCH BY CITATION

References

  • 1
    Ajibade D, Benn BS, Christakos S. Mechanism of action of 1,25-dihydroxyvitamin D3 on intestinal calcium absorption and renal calcium transport. In: Holick MF, ed. Vitamin D: Physiology, molecular biology, and clinical applications, 2nd ed. New York: Human Press; 2010, pp 17587.
  • 2
    Bilezikian JP, Marcus R, Levine MA. The molecular genetics of hypoparathyroidism. In: The parathyroids: basic and clinical concepts. San Diego, CA: Academic Press; 2001, pp 77990.
  • 3
    Shoback D. Clinical practice. Hypoparathyroidism. N Engl J Med. 2008 July; 359:391403.
  • 4
    Bilezikian JP, Marcus R, Levine MA. Autoimmune hypoparathyroidism: the parathyroid glands, 2nd ed. San Diego, CA: Academic Press; 2001, pp 791806.
  • 5
    Horwitz MJ, Stewart AF. Hypoparathyroidism: is it time for replacement therapy? J Clin Endocrinol Metab. 2008 Sept; 93:33079.
  • 6
    Arlt W, Fremerey C, Callies F, Reincke M, Schneider P, Timmermann W, Allolio B. Well-being, mood and calcium homeostasis in patients with hypoparathyroidism receiving standard treatment with calcium and vitamin D. Eur J Endocrinol. 2002 Feb; 146:21522.
  • 7
    Velasco PJ, Manshadi M, Breen K, Lippmann S. Psychiatric aspects of parathyroid disease. Psychosomatics. 1999 Nov; 40:48690.
  • 8
    Winer KK, Yanovski JA, Cutler GB Jr. Synthetic human parathyroid hormone 1–34 vs calcitriol and calcium in the treatment of hypoparathyroidism. JAMA. 1996 Aug; 276:6316.
  • 9
    Winer KK, Yanovski JA, Sarani B, Cutler GB Jr. A randomized, cross-over trial of once-daily versus twice-daily parathyroid hormone 1–34 in treatment of hypoparathyroidism. J Clin Endocrinol Metab. 1998 Oct; 83:34806.
  • 10
    Winer KK, Ko CW, Reynolds JC, Dowdy K, Keil M, Peterson D, Gerber LH, McGarvey C, Cutler GB Jr. Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone-(1–34) versus calcitriol and calcium. J Clin Endocrinol Metab. 2003 Sept; 88:421420.
  • 11
    Winer KK, Sinaii N, Peterson D, Sainz B Jr., Cutler GB Jr. Effects of once versus twice-daily parathyroid hormone 1–34 therapy in children with hypoparathyroidism. J Clin Endocrinol Metab. 2008 Sept; 93:338995.
  • 12
    Winer KK, Sinaii N, Reynolds J, Peterson D, Dowdy K, Cutler GB Jr. Long-term treatment of 12 children with chronic hypoparathyroidism: a randomized trial comparing synthetic human parathyroid hormone 1–34 versus calcitriol and calcium. J Clin Endocrinol Metab. 2010 Jun; 95:26808.
  • 13
    Rubin MR, Sliney J Jr., McMahon DJ, Silverberg SJ, Bilezikian JP. Therapy of hypoparathyroidism with intact parathyroid hormone. Osteoporos Int. 2010 Nov; 21:192734.
  • 14
    Hermann AP. Assessment of calcium intake. A quick method comparerd to a 7 days food diary. In: Thomsen J, Vestergaard P, Mosekilde L, Charles P (eds.), 64 (suppl 1) ed., p. 82.
  • 15
    Abrahamsen B, Gram J, Hansen TB, Beck-Nielsen H. Cross calibration of QDR-2000 and QDR-1000 dual-energy X-ray densitometers for bone mineral and soft-tissue measurements. Bone. 1995 Mar; 16:38590.
  • 16
    Mosekilde L, Beck-Nielsen H, S°rensen OH, Nielsen SP, Charles P, Vestergaard P, Hermann AP, Gram J, Hansen TB, Abrahamsen B, Ebbesen EN, Stilgren L, Jensen LBr, Brot C, Hansen B, Tofteng CL, Eiken P, Kolthoff N. Hormonal replacement therapy reduces forearm fracture incidence in recent postmenopausal women – results of the Danish Osteoporosis Prevention Study. Maturitas. 2000 Oct; 36:18193.
  • 17
    Transbol I, Hornum I, Hahnemann S, Hasner E, Ohlenschlaeger H, Diemer H, Lockwood K. Tubular reabsorption of calcium in the differential diagnosis of hypercalcaemia. Further experience. Acta Med Scand. 1970 Dec; 188:50522.
  • 18
    Bijvoet OLM, Morgan DB, Fourman P. The assessment of phosphate reabsorption. Clinica Chimica Acta. 1969 Oct; 26:1524.
  • 19
    Maunsell Z, Wright DJ, Rainbow SJ. Routine Isotope-Dilution Liquid Chromatography-Tandem Mass Spectrometry Assay for Simultaneous Measurement of the 25-Hydroxy Metabolites of Vitamins D2 and D3. Clin Chem. 2005 Sept; 51:168390.
  • 20
    Hojskov CS, Heickendorff L, Moller HJ. High-throughput liquid-liquid extraction and LCMSMS assay for determination of circulating 25(OH) vitamin D3 and D2 in the routine clinical laboratory. Clinica Chimica Acta. 2010 Jan; 411:1146.
  • 21
    Rosenquist C, Qvist P, Bjarnason N, Christiansen C. Measurement of a more stable region of osteocalcin in serum by ELISA with two monoclonal antibodies. Clin Chem. 1995 Oct; 41:143945.
  • 22
    Hanson DA, Weis MA, Bollen AM, Maslan SL, Singer FR, Eyre DR. A specific immunoassay for monitoring human bone resorption: Quantitation of type I collagen cross-linked N-telopeptides in urine. J Bone Miner Res. 1992;7:12518.
  • 23
    Kantham L, Quinn SJ, Egbuna OI, Baxi K, Butters R, Pang JL, Pollak MR, Goltzman D, Brown EM. The calcium-sensing receptor (CaSR) defends against hypercalcemia independently of its regulation of parathyroid hormone secretion. Am J Physiol Endocrinol Metab. 2009 Oct; 297:E91523.
  • 24
    Riccardi D, Brown EM. Physiology and pathophysiology of the calcium-sensing receptor in the kidney. Am J Physiol Renal Physiol. 2010 Mar; 298:F48599.
  • 25
    Kuro-o M. Overview of the FGF23-Klotho axis. Pediatr Nephrol. 2010 Apr; 25:58390.
  • 26
    Juppner H. Phosphate and FGF-23. Kidney Int. Suppl. 2011 Apr; (121):S247.
  • 27
    Bergwitz C, Juppner H. Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23. Annu Rev Med. 2010;61:91104.
  • 28
    KREMER RICH, GOLTZMAN DAVI. Parathyroid hormone stimulates mammalian renal 25-Hydroxyvitamin D3-1{alpha}-hydroxylase in vitro. Endocrinology. 1982 Jan; 110:2946.
  • 29
    Murayama A, Takeyama Ki, Kitanaka S, Kodera Y, Kawaguchi Y, Hosoya T, Kato S. Positive and Negative Regulations of the Renal 25-Hydroxyvitamin D3 1α-Hydroxylase Gene by Parathyroid Hormone, Calcitonin, and 1{alpha},25(OH)2D3 in Intact Animals. Endocrinology. 1999 May; 140:222431.
  • 30
    Davies M, Heys SE, Selby PL, Berry JL, Mawer EB. Increased catabolism of 25-hydroxyvitamin D in patients with partial gastrectomy and elevated 1,25-dihydroxyvitamin D levels. Implications for metabolic bone disease. J Clin Endocrinol Metab. 1997 Jan; 82:20912.
  • 31
    Rubin MR, Manavalan JS, Dempster DW, Shah J, Cremers S, Kousteni S, Zhou H, McMahon DJ, Kode A, Sliney J, Shane E, Silverberg SJ, Bilezikian JP. Parathyroid hormone stimulates circulating osteogenic cells in hypoparathyroidism. J Clin Endocrinol Metab. 2011 Jan; 96:17686.
  • 32
    Parfitt AM. The actions of parathyroid hormone on bone: relation to bone remodeling and turnover, calcium homeostasis, and metabolic bone disease. Part III of IV parts; PTH and osteoblasts, the relationship between bone turnover and bone loss, and the state of the bones in primary hyperparathyroidism. Metabolism. 1976 Sept; 25:103369.
  • 33
    Bilezikian JP. Combination anabolic and antiresorptive therapy for osteoporosis: opening the anabolic window. Curr Osteoporos Rep. 2008 Mar; 6:2430.
  • 34
    Saag KG, Shane E, Boonen S, Marin F, Donley DW, Taylor KA, Dalsky GP, Marcus R. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med. 2007 Nov; 357:202839.
  • 35
    Greenspan SL, Bone HG, Ettinger MP, Hanley DA, Lindsay R, Zanchetta JR, Blosch CM, Mathisen AL, Morris SA, Marriott TB. Effect of recombinant human parathyroid hormone (1–84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med. 2007 Mar; 146:32639.
  • 36
    Rubin MR, Dempster DW, Zhou H, Shane E, Nickolas T, Sliney J Jr, Silverberg SJ, Bilezikian JP. Dynamic and structural properties of the skeleton in hypoparathyroidism. J Bone Miner Res. 2008 Dec; 23:201824.
  • 37
    Chan FK, Tiu SC, Choi KL, Choi CH, Kong AP, Shek CC. Increased bone mineral density in patients with chronic hypoparathyroidism. J Clin Endocrinol Metab. 2003 July; 88:31559.
  • 38
    Langdahl BL, Mortensen L, Vesterby A, Eriksen EF, Charles P. Bone histomorphometry in hypoparathyroid patients treated with vitamin D. Bone. 1996 Feb; 18:1038.
  • 39
    2011 Forsteo product information.
  • 40
    2011 Preotact product information.
  • 41
    Trivedi R, Mithal A, Chattopadhyay N. Recent updates on the calcium-sensing receptor as a drug target. Curr Med Chem. 2008;15:17886.
  • 42
    Marie PJ. The calcium-sensing receptor in bone cells: a potential therapeutic target in osteoporosis. Bone. 2010 Mar; 46:5716.